A new drug that is quick to reach blockbuster status – or $1bn in revenues – is often a sign of a mega-blockbuster in the making. Launch trajectories are a closely watched metric to evaluate a new drug’s likelihood of long-term commercial success.
Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?
Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.

More from New Products
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
More from Scrip
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.